Medicines Co. (MDCO) Posts Q1 Loss of $1.03/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Chiesi to Acquire Medicines Co.'s (MDCO) Cleviprex, Kengreal, and Rights to Argatroban
May 9, 2016 7:08 AM EDTThe Medicines Company (NASDAQ: MDCO) announced that it has entered into a definitive agreement to sell Cleviprex (clevidipine), Kengreal (cangrelor) and the Companys rights to Argatroban for Injection to Chiesi USA, Inc. and its parent company, Chiesi Farmaceutici S.p.A., for up to $792 million, consisting of $260 million in cash payable at closing, up to $480 million in sales-based milestone payments, the assumption by Chiesi of up to $50... More
